Exact Sciences Corp stock delisted from Nasdaq after $21 billion Abbott acquisition completion

Abbott Laboratories has finalized its $21 billion cash acquisition of Exact Sciences Corp (ISIN: US30063P1057), converting shares into $105 each and delisting EXAS from Nasdaq on March 23, 2026. This landmark deal reshapes cancer diagnostics, offering US investors clarity on payouts while boosting Abbott's growth in screening technologies.

Abbott Laboratories completed its $21 billion acquisition of Exact Sciences Corp on March 23, 2026, marking the end of independent trading for the Exact Sciences Corp stock on Nasdaq. Shareholders received $105 per share in cash, a substantial premium that propelled the stock's value over the past year. Trading halted prior to market open, with delisting requested immediately after the merger closed through Abbott's subsidiary, Badger Merger Sub I.

As of: 23.03.2026

By Dr. Elena Voss, Senior Biotech Market Analyst – Tracking oncology diagnostics mergers and their impact on precision medicine pipelines for global investors.

Acquisition Closure: Key Deal Terms and Immediate Impacts

The merger converted each outstanding share of Exact Sciences common stock into the right to receive $105 in cash, excluding dissenting shares. This valued the deal at approximately $21 billion, funded by Abbott's cash reserves and debt. Convertible notes now convert solely into cash based on the $105 price, while stock options and equity awards were cashed out or assumed by Abbott with adjusted terms.

Exact Sciences board members and officers resigned at closing. The company's certificate of incorporation and bylaws were amended. Nasdaq received notification for delisting and deregistration, suspending SEC reporting obligations. This swift closure followed shareholder approval on February 20, with 67.56% in favor, and all regulatory clearances secured by March 20.

For US investors holding Exact Sciences Corp stock, payout processing begins promptly. Brokerages will handle conversions, though minor delays may occur for complex holdings like options or notes. The premium rewarded patience, as shares had doubled in six months amid acquisition speculation.

Strategic Rationale: Abbott Enters High-Growth Cancer Screening

Abbott positions the acquisition as entry into the fast-growing $60 billion US cancer screening and precision oncology market. Exact Sciences brings market-leading products like Cologuard for noninvasive colorectal screening, Oncotype DX for breast cancer treatment guidance, Oncodetect for molecular residual disease monitoring, and Cancerguard multi-cancer early detection blood test.

These complement Abbott's diagnostics strengths in lab and point-of-care testing, such as FreeStyle Libre for diabetes. Abbott plans to leverage its vast primary care salesforce to expand Cologuard adoption. The deal accelerates innovation in preventative, predictive diagnostics amid rising global cancer incidence.

CEO Robert B. Ford emphasized portfolio shaping for long-term value. Integration promises synergies in sales and R&D, targeting millions more patients for early detection. Federal Medicare coverage for multi-cancer tests further validates the sector's momentum.

Financial Implications for Abbott and Former EXAS Holders

Abbott expects $3 billion incremental sales in 2026 from Exact Sciences, boosting overall growth by 0.5%. However, adjusted EPS dilutes by $0.20 this year due to integration costs and debt interest. Accretion begins in 2028 as synergies mature.

Exact Sciences reported $3.25 billion revenue last twelve months but a $1.10 per share loss. Analysts forecasted profitability with $1.27 EPS this year. The $105 payout exceeds recent trading levels, providing clean exits for US investors.

Convertible notes and equity plans transitioned smoothly. Accelerated executive bonuses addressed tax issues pre-close. Marshall Financial Group recently bought shares, signaling confidence in the premium before closure.

Why US Investors Should Monitor Abbott Post-Deal

US investors shift focus to Abbott (NYSE: ABT) shares for exposure to Exact Sciences' pipeline. The acquisition neutralizes competition in liquid biopsy and secures turnkey growth. Analysts like UBS praise portfolio complementarity, eyeing cross-selling via Abbott's sales network.

Cancer screening demand surges with aging populations and policy support. Medicare's multi-cancer pathway enhances reimbursement prospects. Abbott's scale accelerates Exact Sciences' next-gen tests, potentially capturing larger market share.

For German-speaking investors in Germany, Austria, and Switzerland, this underscores US biotech consolidation trends. Holding Abbott via diversified portfolios maintains oncology upside without single-stock risk. Watch integration execution for EPS recovery signals.

Oncology Sector Dynamics Amplified by the Merger

Exact Sciences led noninvasive colorectal screening with Cologuard, capturing significant market share. Oncotype DX guides breast cancer therapy, reducing overtreatment. Emerging tests like Cancerguard target multi-cancer detection via blood, aligning with shift to liquid biopsies.

Abbott's resources fast-track pipeline advancement. Rivals face heightened competition in MRD testing and recurrence monitoring. Rising cancer rates globally, per WHO data, fuel demand for early diagnostics, where Exact Sciences excelled.

Integration risks include cultural clashes and R&D overlaps. Yet, complementary portfolios minimize antitrust hurdles, as regulators approved swiftly. Mizuho's downgrade to Neutral reflected post-merger dynamics, despite raised targets.

Risks and Open Questions in Integration Phase

Short-term EPS dilution pressures Abbott amid nutrition segment challenges. Debt from financing adds interest costs. Execution risks loom in salesforce integration and pipeline prioritization.

Convertible note conversions could trigger cash outflows. Former Exact Sciences employees face retention hurdles. Regulatory shifts, like Medicare expansions, carry policy risks if reversed.

US investors weigh Abbott's track record in diagnostics M&A. Successful FreeStyle Libre ramps suggest capability. Monitor Q2 earnings for early integration metrics and sales ramp evidence.

Broader Market Relevance for Global Investors

This deal signals consolidation in precision oncology, favoring scaled players. Abbott's move counters post-COVID diagnostics slowdowns. US investors benefit from premium payouts and Abbott exposure.

German-speaking audiences track via DAX-linked health ETFs or direct ABT holdings. Sector tailwinds persist with aging demographics. Long-term, combined entity pioneers personalized cancer care.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.